Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EPS (Weighted Average and Diluted) (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.61 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 365.22% to -$0.61 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.73, a 62.76% increase, with the full-year FY2025 number at -$0.73, up 62.37% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.61 for Q4 2025 at GeneDx Holdings, down from -$0.26 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $387.51 in Q3 2021 to a low of -$348.82 in Q1 2021.
  • A 5-year average of -$3.3 and a median of -$1.01 in 2023 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 2972.45% in 2022, then skyrocketed 133.64% in 2025.
  • GeneDx Holdings' EPS (Weighted Average and Diluted) stood at $0.98 in 2021, then tumbled by 2972.45% to -$28.15 in 2022, then surged by 96.73% to -$0.92 in 2023, then surged by 125.0% to $0.23 in 2024, then crashed by 365.22% to -$0.61 in 2025.
  • Per Business Quant, the three most recent readings for WGS's EPS (Weighted Average and Diluted) are -$0.61 (Q4 2025), -$0.26 (Q3 2025), and $0.37 (Q2 2025).